Michele Cavo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michele cavo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michele Cavo Today - Breaking & Trending Today

Practice-changing study on bone marrow cancer therapy

Practice-changing study on bone marrow cancer therapy
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Michele Cavo , Meral Beksac , Aurore Perrot , Cyrille Hulin , Meletiosa Dimopoulos , Hermann Einsele , Mario Boccadoro , Silvia Mangiacavalli , Xavier Leleu , Pieter Sonneveld , European Myeloma Network , Janssen Research , University Hospital , National Tumour Centre , Medical Clinic , European Myeloma , New England Journal , Hang Quach , Elisabetta Antonioli ,

COVID-19 Collection

COVID-19 Collection
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Fen Zhou , Djamal Khimoud , Mrinalm Patnaik , Jeremyl Warner , Rogerjs Preston , Thomas Kander , Debora Joseph Pietras , Torunno Apelseth , Royf Chemaly , Christopher Pleyer , Saskia Middeldorp , Carolyn Doree , Jenni Bloomquist , Nicola Campbell , Maximilian Stahl , Dennis Mc Gonagle , Alexander Zoufaly , Akshay Sharma , Jan Philipp Bewersdorf , Robynl Shea , Jenneke Leentjens , Ann Ocallaghan , Prajwalc Boddu , Samuelm Rubinstein ,

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

Credit: Dana-Farber Cancer Institute
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the
New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses, are significantly better than those produced by currently available therapies for patients with multiple relapses, according to investigators. ....

New York , United States , Nordrhein Westfalen , Region Flamande , Comunidad Autonoma De Cataluna , San Francisco , Dana Farber Cancer Institute , Baden Wuberg , United Kingdom , Institut Catala , Liping Huang , Triasi Pujol , Alessandro Rambaldi , Donna Reece , Nikhil Munshi , Jamien Connarn , Monica Massaro , David Siegel , Shari Kaiser , Nina Shah , Deepu Madduri , Michele Cavo , Hermann Einsele , Territoriale Papa Giovanni , Philippe Moreau , Yi Lin ,